HAVCR2 and colorectal carcinoma: We investigated TIM-3 expression on CD3+, CD3+CD4+, and CD3+CD4−(CD8+) T cells in PBMC from 34 CRC patients, and NILs and TILs from 27 CRC patients using flow cytometry.